ReviewJournal of thoracic disease2020
Noninvasive biomarkers for lung cancer diagnosis, where do we stand?
Review in Journal of thoracic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05738031 (Investigating Incidental Pulmonary Nodules in Underserved Communities), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigating Incidental Pulmonary Nodules in Underserved Communities
Who cites it
24 citing papers in PubMed.
- Article
- AptoDetect™-Lung Assay as a Blood-Based Predictor of Advanced-Stage Lung Cancer in Patients with Lung-RADS 3-4 Pulmonary Nodules: A Multicenter Prospective Cohort Study.Biomedicines · 2026Article
- Biomarkers for the diagnosis of indeterminate pulmonary nodules: are we there yet?Journal of thoracic disease · 2025Review
- Radiomic 'Stress Test': exploration of a deep learning radiomic model in a high-risk prospective lung nodule cohort.BMJ open respiratory research · 2025Article
- Translating premalignant biology to accelerate non-small-cell lung cancer interception.Nature reviews. Cancer · 2025Review
- A Thorough Review of the Clinical Applications of Artificial Intelligence in Lung Cancer.Cancers · 2025Review
- Integrated multiomics signatures to optimize the accurate diagnosis of lung cancer.Nature communications · 2025Article
- Fusion of CT radiomics and autoantibody biomarkers for enhanced prediction of lung cancer diagnosis: a comprehensive study.Frontiers in oncology · 2025Article
- Radiomics and artificial intelligence for risk stratification of pulmonary nodules: Ready for primetime?Cancer biomarkers : section A of Disease markers · 2025Review
- Biomarkers in lung cancer diagnosis and bronchoscopy: Current landscape and future directions.Cancer biomarkers : section A of Disease markers · 2025Review
- Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment.Archivos de bronconeumologia · 2024Review
- Potential for trans-pulmonary tumor markers in the early diagnosis of lung cancer: a case report.BMC pulmonary medicine · 2024Article
- Article
- Validation of a Proteomic Signature of Lung Cancer Risk from Bronchial Specimens of Risk-Stratified Individuals.Cancers · 2023Article
- Circulating proteome for pulmonary nodule malignancy.Journal of the National Cancer Institute · 2023Article
- Longitudinal lung cancer prediction convolutional neural network model improves the classification of indeterminate pulmonary nodules.Scientific reports · 2023Article
- Comparing modalities for risk assessment in patients with pulmonary lesions and nondiagnostic bronchoscopy for suspected lung cancer.BMC pulmonary medicine · 2022Article
- Artificial Intelligence Tool for Assessment of Indeterminate Pulmonary Nodules Detected with CT.Radiology · 2022Article
- Article
- The impact of the lung EDRN-CVC on Phase 1, 2, & 3 biomarker validation studies.Cancer biomarkers : section A of Disease markers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The 2010's saw demonstration of the power of lung cancer screening to reduce mortality. However, with implementation of lung cancer screening comes the challenge of diagnosing millions of lung nodules every year. When compared to other cancers with widespread screening strategies (breast, colorectal, cervical, prostate, and skin), obtaining a lung nodule tissue biopsy to confirm a positive screening test remains associated with higher morbidity and cost. Therefore, non-invasive diagnostic biomarkers may have a unique opportunity in lung cancer to greatly improve the management of patients at risk. This review covers recent advances in the field of liquid biomarkers and computed tomographic imaging features, with special attention to new methods for combination of biomarkers as well as the use of artificial intelligence for the discrimination of benign from malignant nodules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.